Abstract:Histone deacetylases (HDACs) represent an expanding family of protein modifying-enzymes that play important roles in cell proliferation, chromosome remodeling, and gene transcription. We have previously shown that recombinant human HDAC8 can be expressed in bacteria and retain its catalytic activity. To further explore the catalytic activity of HDACs, we expressed two additional human class I HDACs, HDAC1 and HDAC3, in baculovirus. Recombinant HDAC1 and HDAC3 fusion proteins remained soluble and catalytically active and were purified to near homogeneity. Interestingly, trichostatin (TSA) was found to be a potent inhibitor for all three HDACs (IC50 value of approximately 0.1-0.3 microM), whereas another HDAC inhibitor MS-27-275 (N-(2-aminophenyl)-4-[N-(pyridin-3-methyloxycarbonyl)-aminomethyl]benzamide) preferentially inhibited HDAC1 (IC50 value of approximately 0.3 microM) versus HDAC3 (IC50 value of approximately 8 microM) and had no inhibitory activity toward HDAC8 (IC50 value >100 microM). MS-27-275 as well as TSA increased histone H4 acetylation, induced apoptosis in the human colon cancer cell line SW620, and activated the simian virus 40 early promoter. HDAC1 protein was more abundantly expressed in SW620 cells compared with that of HDAC3 and HDAC8. Using purified recombinant HDAC proteins, we identified several novel HDAC inhibitors that preferentially inhibit HDAC1 or HDAC8. These inhibitors displayed distinct properties in inducing histone acetylation and reporter gene expression. These results suggest selective HDAC inhibitors could be identified using recombinantly expressed HDACs and that HDAC1 may be a promising therapeutic target for designing HDAC inhibitors for proliferative diseases such as cancer.

Discovery of Meta-Sulfamoyl N-hydroxybenzamides As HDAC8 Selective Inhibitors

HDAC8 as a target in drug discovery: Function, structure and design

Discovery of Histone Deacetylase 8 Selective Inhibitors

Discovery of A Series of Hydroximic Acid Derivatives As Potent Histone Deacetylase Inhibitors

Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8

Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group.

Design, Synthesis, and Antiproliferative Activity of Selective Histone Deacetylases 6 Inhibitors Containing a Tetrahydropyridopyrimidine Scaffold

Development of N-hydroxybenzamide Derivatives with Indole-Containing Cap Group As Histone Deacetylases Inhibitors

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

Design, Synthesis and Primary Activity Assay of Tripeptidomimetics As Histone Deacetylase Inhibitors with Linear Linker and Branched Cap Group

Discovery and Preliminary Evaluation of 2-Aminobenzamide and Hydroxamate Derivatives Containing 1,2,4-Oxadiazole Moiety As Potent Histone Deacetylase Inhibitors.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design, Synthesis, and Biological Evaluation of 1, 3-Disubstituted-pyrazole Derivatives As New Class I and IIb Histone Deacetylase Inhibitors

Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases

Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.

Identification of A Novel Aminotetralin Class of Hdac6 and Hdac8 Selective Inhibitors

Discovery of 1,2,4-Oxadiazole-containing Hydroxamic Acid Derivatives As Histone Deacetylase Inhibitors Potential Application in Cancer Therapy.

Design, Synthesis and Biological Evaluation of 3, 4-Disubstituted-imidazolidine-2, 5-Dione Derivatives As HDAC6 Selective Inhibitors

Design, Synthesis and Bioactivity Evaluations of 8-Substituted-quinoline-2-carboxamide Derivatives As Novel Histone Deacetylase (HDAC) Inhibitors.

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Design, synthesis and antitumor activity evaluation of novel benzamide HDAC inhibitors